MRSN Live signaler | Maksimer profitt med Getagraph.com

KJøP 110206 min ago

@ $3.79

Utstedt: 14 feb 2024 @ 19:46

Avkastning: -16.36%

Forrige signal: feb 14 - 15:30

Forrige signal: Selg

Avkastning: -3.33 %

Live Chart Being Loaded With Signals

Commentary (30 apr 2024 @ 22:00):

Stats
Dagens volum	1.16M
Gjennomsnittsvolum	2.23M
Markedsverdi	382.24M
EPS	$0 ( 2024-02-27 )
Neste inntjeningsdato	( $-0.180 ) 2024-05-07
Last Dividend	$0 ( N/A )
Next Dividend	$0 ( N/A )
P/E	-1.800
ATR14	$0.00800 (0.25%)

Insider Trading

Date	Person	Action	Amount	type
2024-04-01	Alleva Lawrence M	Buy	3 996	Stock Option (right to buy)
2024-01-13	Mandelia Ashish	Buy	0
2024-01-15	Protopapas Anna	Buy	17 708	Common Stock
2024-01-15	Protopapas Anna	Buy	21 250	Common Stock
2024-01-16	Protopapas Anna	Sell	29 399	Common Stock

INSIDER POWER
74.95
Last 98 transactions
Buy: 4 017 838 \| Sell: 585 969

Volum Korrelasjon

Lang: -0.35 (neutral)

Kort: 0.28 (neutral)

Signal:(47.61) Neutral

Mersana Therapeutics Inc Korrelasjon

10 Mest positive korrelasjoner

10 Mest negative korrelasjoner

Visste du det?

Korrelasjon er en statistisk måling som beskriver forholdet mellom to variabler. Den varierer fra -1 til 1, hvor -1 indikerer en perfekt negativ korrelasjon (hvor en variabel øker, går den andre ned), 1 indikerer en perfekt positiv korrelasjon (hvor en variabel øker, går den andre også opp), og 0 indikerer ingen korrelasjon (det er ingen forhold mellom variablene).

Korrelasjon kan brukes til å analysere forholdet mellom to variabler, ikke bare aksjer. Det er vanligvis brukt innen områder som finans, økonomi, psykologi, og mer.

Mersana Therapeutics Inc Korrelasjon - Valuta/Råvare

-0.34
( neutral )

-0.63
( weak negative )

-0.66
( moderate negative )

-0.62
( weak negative )

0.25
( neutral )

Mersana Therapeutics Inc Økonomi

Annual	2023
Omsetning:	$36.86M
Bruttogevinst:	$35.34M (95.88 %)
EPS:	$-1.480

FY	2023
Omsetning:	$36.86M
Bruttogevinst:	$35.34M (95.88 %)
EPS:	$-1.480

FY	2022
Omsetning:	$26.58M
Bruttogevinst:	$25.65M (96.51 %)
EPS:	$-2.22

FY	2021
Omsetning:	$43 000.00
Bruttogevinst:	$0.00 (0.00 %)
EPS:	$-2.37

Financial Reports:

No articles found.

Mersana Therapeutics Inc

Mersana Therapeutics, Inc., a clinical stage biopharmaceutical company, develops antibody drug conjugates (ADC) for cancer patients with unmet need. It develops XMT-1592, a Dolasynthen ADC targeting NaPi2b-expressing tumor cells, which is in phase I clinical trial for the treatment of ovarian cancer and NSCLC adenocarcinoma. The company also develops XMT-1660, a B7-H4-targeted Dolasynthen ADC candidate; and XMT-2056, an immunosynthen development candidate. It has a strategic research and development partnerships with Merck KGaA and Asana BioSciences, LLC for the development of ADC product candidates utilizing Fleximer. The company was formerly known as Nanopharma Corp. and changed its name to Mersana Therapeutics, Inc. in November 2005. Mersana Therapeutics, Inc. was incorporated in 2001 and is headquartered in Cambridge, Massachusetts.